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Abstract12
With the recent clinical implementation of real-time MRI guided x-ray beam therapy (MRXT), attention is13
turning to the concept of combining real-time MRI guidance with proton beam therapy; MRI guided proton beam14
therapy (MRPT). MRI guidance for proton beam therapy is expected to oer a compelling improvement to the15
current treatment workow which is warranted arguably more than for x-ray beam therapy. This argument is born16
out of the fact that proton therapy toxicity outcomes are similar to that of the most advanced IMRT treatments,17
despite being a fundamentally superior particle for cancer treatment.18
In this Future of Medical Physics article we describe the various software and hardware aspects of potential19
MRPT systems and the corresponding treatment workow. Signicant software developments, particularly focused20
around adaptive MRI based planning will be required. The magnetic interaction between the MRI and the proton21
beamline components will be a key area of focus. For example, the modeling and potential redesign of a magnetically22
compatible gantry to allow for beam delivery from multiple angles towards a patient located within the bore of an23
MRI scanner. Further to this, the accuracy of pencil beam scanning and beam monitoring in the presence of an24
MRI fringe eld will require modeling, testing, and potential further development to ensure that the highly targeted25
radiotherapy is maintained.26
Looking forward we envisage a clear and accelerated path for hardware development, leveraging from lessons27
learnt from MRXT development. Within a few years simple prototype systems will likely exist, and in a decade we28
could envisage coupled systems with integrated gantries. Such milestones will be key in the development of a more29
ecient, more accurate, and more successful form of proton beam therapy for many common cancer sites.30
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1. INTRODUCTION32
1.A. Rationale for MRPT33
A fundamental tenet in radiotherapy is that a decrease in dose will lead to a decrease in normal tissue toxicity. This34
principle has been examined and in many cancer sites supported as summarised through the QUANTEC reports[1].35
Based on the physics and multiple planning studies of both passively scattered and actively scanned proton therapy,36
we would expect proton therapy to show markedly reduced clinical toxicity. However, this expectation is yet to be37
realised. A retrospective medical claims review of 27,000 IMRT patient and 550 proton therapy patients shows no38
statistically signicant dierence in toxicity[2]. Similarly, in a prospective randomized clinical trial (NCT00915005)39
of locally advanced non-small cell lung cancer, radiation pneumonitis was lower in the IMRT arm than the proton40
therapy arm[3]. This mismatch between expected and observed outcomes leads to a compelling hypothesis: advanced41
image guidance is required to realise the clinical potential of proton therapy.42
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Given the longer history and larger number of systems, advanced image guidance in x-ray therapy is far ahead of43
proton therapy. A new and fast-growing area of x-ray based therapy are integrated MRI-x-ray systems. MRI oers44
the potential for both real-time anatomic imaging and also physiologic imaging with the patient in the treatment45
position. Merging MRI with proton therapy provides a compelling opportunity to realise the clinical potential of46
proton therapy and also explore further improvements in patient care through monitoring and adapting to changing47
tumour and normal tissue physiology throughout a course of radiotherapy.48
As a nal note, we consider the recent Point/Counterpoint article by Paganetti and Yu[4] entitled "Photon ra-49
diotherapy has reached its limit in terms of catching up dosimetrically with proton therapy". In this discussion the50
\ceiling" for proton therapy quality is described as being higher than for photons, despite not being reached yet in51
either discipline. A development that would signicantly raise both the quality and the ceiling of proton therapy is52
that of the implementation of real-time MRI guidance.53
54
1.B. Current state of the art in MRXT55
56
Real-time Magnetic Resonance or MR guided x-ray beam radiotherapy, MRXT, was launched clinically in 2014 with57
the introduction of the ViewRay MRIdian system, consisting of a 0.35 T MRI scanner coupled with a 3-head Cobalt-6058
radiation source[5]. At present 6 sites around the world are operating with the MRIdian system[6], with at least 259
more conrmed for operation in early 2017[7]. Development and progress of this system is detailed in no less than 1860
articles[8]. We also note the development of the linac based MRIdian system for non-clinical research[9]. Production of61
other pre-clinical linac based MRXT systems is also well underway with the development of the Philips-Elekta system62
Atlantic[10]. This consists of a Philips 1.5 T MRI scanner coupled with an Elekta 7MV linear accelerator. Currently,63
these systems are still being installed and tested under a research consortium arrangement in 7 sites around the64
world[11]. Clinical treatments are planned before the end of 2017, and at least 37 publications are listed related to the65
development of the worlds rst high eld MRI guided x-ray therapy system. Another commerical linac based program66
by MagnetTx[12] is developing the Aurora RT system, consisting of a 6MV x-ray beam and a rotating bi-planar 0.567
T magnet with an iron yoke[13]. This program describes 44 publications around the development of the worlds rst68
inline orientation MRI-linac system.[14] Finally there is a 1 T split-bore magnet research system under development69
at the Ingham Institute in Sydney Australia[15, 16]. This system is the worlds rst high eld strength inline system70
with an air-core MRI. At present at least 30 publications are related to this program.[17]71
72
1.C. Existing literature in MRPT73
74
Considering the potential improvements of MRPT over conventional proton therapy as oulined in the Section 1.A.,75
various groups have performed simulation based studies of the feasibility of some aspects of MRPT. Several studies76
have looked at the fundamental beam transport and dosimetry changes, in particular, the magnitude of the deection77
of proton beams by the strong magnetic elds typically found in the imaging volume of an MRI scanner. These include78
estimation of the deection inside a water phantom by Raaymakers et al.[18] and Wolf and Bortfeld[19]. Optimised79
patient based planning in uniform magnetic elds to account for the imaging eld deection has also been studied by80
Moteabbed et al.[20] and Hartman et al.[21]. These studies assumed a static external magnetic eld without fringe81
eld eects as being the inuence of the MRI scanner. It has been shown recently however, that the fringe eld of an82
MRI scanner has a complex and signicant impact on how a proton beam transports towards the MRI isocentre[22].83
A important implication of this work is that the most reliable method for proton beam delivery in real-time MR84
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guided proton therapy will be the pencil beam scanning method. Passively scattered broad beams, which also contain85
a broad energy range, will deect and distort as they travel through the 3D spatially variant fringe eld and deposit86
their Bragg peaks at locations dierent from the non-magnetic eld case. On the contrary, the pencil beam scanning87
method will require simple spatial correction on a per-pencil-beam basis in order to achieve the correct Bragg-peak88
locations for each pencil beam.89
In the area of MRI-only based planning for protons, several papers have been published. In 2013, Rank et al.90
reported on the use of a classication-based tissue segmentation method based on discriminant analysis to derive so-91
called pseudo CT numbers from MR images of three patients with lesions in the brain[23]. The main issues encountered92
were challenges with assignment of air and bone regions. Dosimetrically, the proton beam plans only had small or93
clinically acceptable deviations from reference CT based comparison plans. Also in 2013, Rank et al. reported on94
a more generic conversion study of MR images for proton beam planning[24]. MRI datasets were acquired for 395
dierent samples of pork chops using up to 8 dierent contrast agents. Again, issues arose related to bone denition96
which led to some more signicant dosimetry dierences with respect to CT based reference dataset plans when using97
proton beams. In 2014, Edmund et al. investigated 5 MRI-based brain tumor cases with proton beam plans[25].98
Pseudo CT datasets were generated by 3 methods including threshold based segmentation, Bayesian segmentation99
and statistical regression. Dose agreement to within 2% was observed with reference CT based plans for the most100
promising statistical regression method. An important nding reported was that the number of tissue grades dened101
impacted the dosimetry match with the reference CT dose plans. In more recent work by Koivula et al.[26], the102
feasibility of using MRI for both brain and prostate cancers has also been studied. In this work substitute CT datasets103
were generated by transforming the intensity values of in-phase MR images to Hounseld units with a dual model104
HU conversion technique to enable heterogeneous tissue representation. Proton plans using the substitute CT dataset105
matched to the reference CT based plans with a 91% gamma pass rate at 1%/1mm tolerance. Overall the authors106
conclude that an MRI-only planning workow is feasible for proton therapy of the investigated brain and prostate107
plans.108
As a nal comment on the current MRPT related literature, we note the 2011 review paper by Schippers and109
Lomax[27]. In this article entitled \Emerging Technologies in Proton Therapy", a small section was dedicated to the110
concept of the integration of MRI with proton therapy. The most challenging aspects were listed as compensation of111
the inuence of the MRI eld on the proton beamline transport magnets, as well as the magnetic eld eects on beam112
monitoring systems.113
In summary, the current literature supports the feasibility of MRI guided proton beam therapy from a fundamental114
patient dosimetry viewpoint. Good progress has been made for MR-only planning of relatively static tumor sites but115
there is a clear need for further development of the more dynamic tumor sites. There are however no studies dedicated116
to the larger scale questions such as the operation of a proton beam delivery system in the presence of an MRI117
scanner, or the design requirements for this unique piece of as yet unreleased advanced radiotherapy equipment. In118
this Future of Medical Physics paper we describe the key software and hardware considerations for development and119
implementation of real-time MRI guided proton beam therapy. Figure 1 provides a summary of these key aspects.120
The various elements in gure 1 are discussed in detail throughout the remainder of this article. Section 2 provides a121
general overview of the potential workow in MRPT. Section 3 summarizes the software considerations starting from122
MR based dose planning to real-time adaptive planning. Section 4 discusses the important hardware considerations123
while Section 5 details various prototype concept designs. Finally in Section 6 our vision for working towards MRPT124
is detailed, with predictions regarding the pathway forward in various key research areas.125
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Figure 1: Schematic diagram of the software and hardware aspects envisaged in the development of MRI guided proton
therapy (MRPT). The key areas of development for an MRI-only workow will be MRI based planning, proton beam
delivery and monitoring in magnetic fringe elds, and adaptive treatment methods.
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2. WORKFLOW IN MRXT AND MRPT126
2.A. MRXT workow127
There are various proposals and methods for the workow of treating patients in MRXT. One such workow which128
is possible on the ViewRay MRIdian system is gated treatments with online adaptive replanning before each fraction to129
account for patient anatomy changes since the last fraction[28]. During this type of approach the patient undergoes an130
MRI scan at the start of each fraction and that information is registered back to the original planning image dataset.131
This original planning dataset may be CT or MRI based, depending on the desired workow. From there, an updated132
or adaptive plan is then produced, and subsequently is delivered with MRI-based gating. In this gating technique the133
beam is delivered only when there is sucient alignment with the real-time observed GTV (or greater organ containing134
the GTV) and the original planning stage GTV. At present, this alignment is based on the real-time sagittal cine MR135
images. A history of the patient anatomy during beam on is also recorded via the MR images obtained, as well as136
a log of the machine and/or radiation beam parameters. This information is then also available for consideration in137
producing the adaptive plan of the next fraction. This process of plan adaptation at the start of each fraction continues138
until all fractions are delivered. The gated adaptive approach is reasonably transparent and so oers condence in139
delivering radiation during real-time MR guidance. The primary downside to this method is the increased treatment140
times through at least three processes: (1) pre-irradiation imaging acquisition, (2) adaptive replanning calculation141
before beam delivery and (3) gating of beam delivery, particularly for highly dynamic tumors. The second point can142
be addressed through fast dose planning calculation methods. One method to avoid the third eect would include143
dynamic MLC tracking movements throughout the entire patient breathing cycle. In this approach there is greater144
post-processing required to combine and register all patient doses and anatomy back to the original static plan. There145
may also be some eects with latency of MLC leaf motion not providing the ideal beam shape with time, however146
preliminary clinical data from non MRI-linac systems is showing great promise[29].147
With regards to patient-specic quality assurance (QA), we note the process followed for the real-time adaptive148
plan QA performed on ViewRay system while the patient is on the treatment couch[30]. In this process, all the updated149
plan details are exported through an independent format, i.e. DICOM, to an in-house dose plan check system based150
on Monte Carlo methods. This system recalculates the new adaptive plan doses independently and provides a gamma151
calculation pass-rate as compared to the original TPS dose prediction. Further to this, setup verication localization152
images are aquired at the start of each fraction, and machine log le analysis is performed after all fractions.153
2.B. MRPT workow154
At rst consideration, an online adaptive replanning workow with static or breath-hold gated treatments would155
be a natural implementation for MRPT. An initial CT scan would be used for planning and all future MRI datasets156
(daily pre-irradiation and intrafractional if acquired) would be registered back to this original CT dataset and plan.157
It would be expected that all treatments be delivered by the pencil beam scanning method for the reasons outlined158
in Section 1.C. In highly static tumor treatments such as brain cancers, the process of imaging, adaptive replan, and159
static treatment will be relatively straight forward. The improvements oered via the onboard MR images will be clear160
over conventional oine CT/MRI methods. Firstly, the patient will be imaged in the treatment position. Secondly,161
any daily anatomy changes and/or tumor margin changes will be known and rened with the highest possible accuracy.162
For each fraction a pencil beam scanning treatment will then cover a tumors' accurately dened 3D target volume163
with zero-dose image guidance.164
In principle, the former process should also be the case for dynamic or moving tumors which are treated with165
breath-hold gating. The 3D outline of a tumor will be known with highest accuracy, over a small timeframe, where166
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fast scanning pencil beams build-up dose to cover the entire treatment volume. The only dierence in this case should167
be longer treatment times to account for the beam-hold durations.168
In the most advanced case of free-breathing treatment there may be some tumor motion while the beam is be-169
ing delivered, depending on cancer type. With pencil beam scanning treatments comes the potential for interplay170
eects[31],[32],[33]. These eects, i.e. possible signicant hot or cold spots within the treatment volume accumulated171
over the course of a single fraction, are shown to be mitigated by fractionation[32], multiple rescanning[33] and re-172
tracking[34]. In the case of MRPT the real-time MR images at the rate of 4-8 frames per second may in fact be173
available to assist in the management of interplay eects. It may be possible to track in real-time a tumor margin and174
correspondingly alter or translate the pencil beam scanning pattern. The exact method will likely take a path that is175
governed by the advances in its accuracy, reproducibility, and proven eectiveness.176
With regards to patient-specic QA, one would expect a workow similar to that outlined in Section 2A for MRXT.177
In the case of proton beam planning however, small anatomy changes may introduce large changes to the pencil beam178
scanning pattern for each beam. We expect that an extra step will be required to determine the robustness of any179
new adaptive plan. Ideally this would be completed quickly at the end of the independent dose calculation.180
In conclusion, the workow in MRPT would likely naturally take a direction similar to that currently unfolding181
in MRXT. The rst stages being daily adaptive replanning for static tumors that have moved or changed over the182
patients' treatment course. The next stages would likely be adaptive replanning with breath-hold gating to ensure183
that a static anatomy is treated. As the modality advances users would be naturally eager to assess the usefulness of184
the real-time MR guidance for dynamic tumors.185
3. SOFTWARE CONSIDERATIONS186
3.A. MRI-only proton therapy planning187
In Section 2.B., the workow described for MRPT assumed the reference plan to be calculated using patient CT188
images. This approach will be the most robust in the early stages of MRPT, as CT based planning is considered189
the best practice for estimation of patient composition for dose planning. In fact recent publications are showing190
promise for proton beam range calculation uncertainties to be in the order of 1% error with the use of dual energy CT191
(DECT)[35, 36, 37]. A potential initial workow in MRPT would then be to register daily MR images back to the192
original planning CT dataset. This would accurately account for any patient anatomy changes, provided that there193
is condence in the deformable image registration process for the given anatomical site. In this process the superior194
soft tissue delineation oered by the MRI data would be registered onto the CT planning dataset. However with195
MRXT, there has been success in directly converting MRI to pseudo or subsitute CT images which can accurately196
reproduce the electron density information used for dose planning[38, 39, 40]. Such methods eliminate the requirement197
to acquire an intial patient CT dataset, whilst preserving the inherent soft tissue delineation shown in the MRI data.198
As described in Section 1.C., similar studies have been performed for proton therapy based planning with mixed but199
promising results. It would appear a natural quest for the pathway of MRPT to be MRI-only planning based, however200
the process needs to be completely robust and superior to the current CT-based planning process. We expect that201
many novel approaches will need to be considered, developed and tested in the path to nding methods for performing202
accurate proton beam dose calculations on MRI datasets.203
3.B. Dose planning in magnetic elds204
In MRXT, the primary therapeutic x-ray beam propagates towards and through the patient and the treatment205
volume without being perturbed by the MRI scanner eld. Dose planning in MRXT can then be modelled (almost206
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entirely) by calculating the magnetic eld induced eects on the dose depositing secondary electrons liberated by207
the primary x-ray beam. The MR imaging volume, by its nature, is highly uniform in direction and magnitude and208
encompasses the patient volume around the isocentre of the MRI scanner. Hence the process of dose planning in209
MRXT is mostly dependent on the nominal strength and direction of the MR imaging eld. We do note however210
various eects on the transport of any air-generated secondary electrons produced by the parent x-ray beam. These211
may be above the patient, or scattered from the patient on the exit side[41, 42, 43, 44, 45, 46, 47, 48, 49, 50].212
With MRPT, the therapeutic proton beam (being charged particles), is subject to the Lorentz deection force213
when transporting towards the patient at the centre of the MRI, as well as within the patient while slowing down.214
The planning process is best broken down into two components as described in gure 1: (a) pencil beam scanning215
and transport towards the planning volume (transport through a fringe eld), and (b) pencil beam transport within216
the planning volume (patient and immediate surrounding volume at xed magnetic eld and direction). These are217
described futher below:218
219
a. Fringe eld transport: pencil beam scanning and fringe eld deection. This will be specic to MRPT design,220
namely the beamline design and integration method between the MRI and scanning magnets. A full accurate model221
and experimental evaluation of this coupled process will be required to accurately determine the properties of the222
pencil beams as they enter the planning volume. Without a magnetic eld, all pencil beams entering the planning223
volume arrive at this boundary with a direction vector that is simply related to how far o-axis the pencil beam is,224
or how much it was scanned. In the case of MRPT this won't be true. There will be complex deections within the225
fringe eld that changes the direction vectors. This is also energy and spatially dependent. Thus this process needs226
to be 'mapped out' for all cases, i.e eld sizes and beam energies. A look-up-table (LUT) of this data for each unique227
MRPT design should then be built and used as input to the next stage of dose planning as outlined in the next section.228
229
b. Patient dose calculation. The patient will be encompassed, for all intensive purposes, by a uniform magnetic230
eld value equal to the MRI strength and direction. Thus dose calculations are straight forward with optimizing231
pencil beamlets, read in from the LUT, that then account for the uniform eld inside the 'planning volume'. The232
latter component of this approach has been performed already in previous works where the extent of the uniform233
imaging eld is 70 cm in diameter[21].234
235
The true advantage of separating the dose planning into the two components mentioned above is that, once part236
(a) is completed for a unique MRPT design, then the LUT of data describing the fringe eld deection and pencil237
beam scanning process can be passed onto independent dose planning engines. The only requirement is that plans238
must be optimised according to the planning volume boundary specied in the LUT. It would therefore be a natural239
quality assurance process to regularly conrm the accuracy of the LUT data against measurements. The integration240
of the MRI and proton beamline would need to be monitored routinely after commissioning.241
3.B.1. Pencil beam scanning and fringe eld correction: an example242
In the previous section the beam modelling through an MRI fringe eld was described. We provide here an example243
of this process for the magnetic eld of the Agilent 1 T split-bore design for the Sydney MRXT prototype[22].244
Figure 2 demonstrates this concept for a simple case in the perpendicular orientation (see Section 4.A.) using simple245
Monte Carlo simulations. In g 2(a) a 170 MeV pencil beam travels into a 30 cm3 water phantom with direction along246
the x-axis without any external magnetic elds. The Bragg-peak occurs at around 190 mm depth, and is located, as247
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expected, on the central axis. The pencil beam started at 2 m from the isocentre, around the same location as they248
would exit the PBS assembly in the IBA Universal Head. This emulates a non-scanned 170 MeV proton pencil beam249
as it exit the PBS assembly.250
In g 2(b) we present the required beam to match the Bragg peak location obtained with g 2(a) when the 1 T251
split-bore MRI eld is present. In this case there is a mostly transverse fringe eld, giving rise to a perpendicular252
deection in the +z direction. Thus one needs to apply a scan setting in the -z direction to reverse this eect. In our253
modeling example this is emulated via a small initial momemtum vector component in the -z direction as detailed.254
The next element to consider is that the path taken to reach the same Bragg-peak location is now longer than the255
non-magnetic eld case. Hence an increase in energy is also required. Using an iterative, forward Monte Carlo trial256
and error process, we have deduced that to align Bragg-peaks, an increase of 3 MeV is required, coupled with a small257
initial -z momentum component. In g 2(c) we see exactly how much the -z momentum shift would relate to without258
a magnetic eld; about 90 mm deection at the isocentre plane. Using this simple example, it can be seen that each259
and every pencil beam (energy and spatial location) will need unique corrections to account for the MRI elds. In the260
rst case, a solution to this issue unique to MRPT is expected to be an experimental process during commissioning261
stages. An appropriate detector system will be required to determine the actual pencil beam location as it crosses262
the detector plane and software would link this to the scanning magnet settings, and beamline energy. From there263
software based static correction maps would be used for beam delivery.264
3.C. Real-time adaptive planning with gated treatments265
The adaptive treatment technique described in Section 2.A. is a natural choice for delivering MRPT. The software266
requirements for this approach include fast online adaptive planning. The process of acquiring the pre-fraction MRI267
and then creating an adaptive plan needs to be performed as quickly as possible while the patient is waiting on the268
treatment couch. At present dose planning for pencil proton beam therapy is performed using both numerical and269
pseudo Monte Carlo based methods. The inclusion of the magnetic elds in the planning volume now needs to be270
considered in these planning stages. Various fast graphical processing unit (GPU) Monte Carlo based calculation271
methods have recently been reported for proton beam therapy planning[51, 52]. Such systems may be ideally suited272
for fast online adaptive replanning, however data transfer rates are further considerations that may limit the speed as273
compared to conventional CPU parallelisation.274
3.D. Real-time adaptive planning with dynamic treatments275
The more advanced treatment case for MRPT is that of dynamic treatments, i.e. a moving PTV is targeted276
dynamically by the proton pencil beams rather than using gating. This approach will require seemless integration277
between the MRI system, planning system, and beamline control system. During treatment, the MR images would278
be processed in real-time to highlight and track the PTV. From there the real-time shifts in the pencil beam will be279
applied so that the delivered dose follows the moving target. It is notably more complicated than MRXT as the beams280
are pencil beams with a dened range (i.e. not broad beams which pass right through the PTV) and so there is some281
time taken to \paint" dose to a moving 3D volume. We can expect that the fundamental limit to the exibility of282
this beam delivery method will be the time required to change the proton beam energy, i.e. Bragg-peak depth. This283
is because the scanning process is controlled rapidly by adjusting scanning bending magnet currents, while changing284
the beam energy typically involves movement of physical graphite attenuators in and out of the beam path.285
In any case, there may be the potential to optimize the beam delivery angle to be perpendicular to the tumor286
motion such that the proton beam energy or range needs minimal adjustment to account for the motion. This287
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Figure 2: Example of the correction to the pencil beam scanning process in the perpendicular orientation. In (a) a 170
MeV pencil beam (without a magnetic eld) is incident along the x-axis (direction vector = [-1 0 0]). The Bragg-peaks
occurs at around 190 mm depth in a water phantom. In (b) a 173 MeV pencil beam is red in the presence of the MRI
eld (perpendicular orientation) with a direction vector of [-1, 0 -0.044]. The Bragg-peak occurs at the same location,
190 mm depth. Without the MRI eld the 173 MeV proton beam would have its Bragg-peak at 197 mm depth, and
90 mm o axis, as shown in (c).
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optimization however does depend on any other changes in the patient anatomy along the beam path which would288
require an energy change. Overall, using an optimized beam delivery angle will take advantage of the fast lateral289
scanning magnet deection process over the slower energy change process. We do note however the study by Chaudri290
et al. which details the feasiblity of using fast magnetic deection (and recovery) of the pencil beam across a static291
degrader wedge to change the energy[53]. Such a method could signicantly reduce the energy changing times over292
conventional moving wedge methods.293
Similarly to gated treatments, it would be expected that all the delivered beam and patient anatomy information294
would be recorded and would form inputs to the adaptive replanning performed at the start of each fraction.295
3.E. Biologically based adaptive planning: potential for subvolume boosting296
From the outset of this section, we note that the radiobiology of proton beams is complex and debated in the297
literature. An excellent review paper has been published by Paganetti[54] which details several of these complexities.298
In the context of the current article it is tting that we describe a vision for how biological information, realized299
through the inherent daily MR images could be used to optimize a patient treatment.300
In the default case, the daily fraction MR images acquired for adaptive planning purposes will be obtained with301
imaging sequences that are designed for anatomical accuracy. It may be possible in MRPT to also acquire image302
datasets with alternate sequences that highlight some element of the underlying biology of the tumors response to the303
radiotherapy. As an example, we shall consider the ability of MRI to determine tumor hypoxia. An excellent review304
and corresponding article have been recently published which details the ability of oxygen-enhanced MRI methods305
to predict tumor hypoxia in mouse subjects[55, 56]. These articles detail compelling arguments for the succesful306
translation of this technology to human subjects. If successful, the daily setup MR images could be complimented307
with these functional images. This information obtained could ultimately guide any decisions to boost dose to say308
some biological hot spot or subvolume within the gross tumor volume. With regards to proton therapy, it may be309
possible to boost dose to specic sub-volumes of the tumor with relative ease, as compared to x-ray therapy. This310
is due to the inherent ease of manipulating the the Bragg-peak within a planning volume without compromising the311
remainder of the treatment plan, or alternately delivering more dose to specic tumour sub-volumes in the pencil312
beam scanning plan. In the case of x-ray beams, boosting to a small sub-volume would often require multiple beam313
angles and hence be a more complex change to the default radiotherapy plan.314
4. HARDWARE CONSIDERATIONS315
4.A. Magnet design requirements316
An ideal magnet design to enable MRPT would be that of a split-bore MRI, such as the General Electric Signa-SP317
where two magnet poles are physically separated by an air gap. This would allow an unobstructed path for the proton318
pencil beam to reach the patient, and then allow this to be incident from many angles perpendicular to the patient319
head-feet axis. With a split-bore design however, there are two approaches in how to position a patient with respect320
to the magnet axis. In the simplest case the patient lies along the bore of the MRI, identical to current MRI scanning.321
Thus the magnetic eld of the MRI scanner (inside the imaging volume) is perpendicular to the radiation beam. This322
is known as the perpendicular (or transverse) orientation. In this orientation the radiation beam can be incident from323
many angles by employing a rotating gantry, or alternately via axial rotation of the patient along the head-feet axis324
using an axially rotating couch system. The alternate case, the inline orientation, is where the patient lies between325
the two halves of a split-bore magnet. The magnetic eld inside the imaging volume is therefore inline (or parallel)326
with the radiation beam direction, which is directed down the magnet bore. With this orientation again you have two327
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options on how to deliver a radiation beam from multiple angles. The simplest case is to axially rotate the patient328
along the head-feet axis via a rotating couch. The second approach is to rotate the entire MRI and radiation source329
around the patient. We note that the Sydney inline MRXT prototype envisages an axially rotating couch while the330
Aurora RT inline MRXT design uses a rotating magnet.331
4.B. Radiofrequency (RF) shielding requirements332
MRI scanners are typically housed inside RF shielded rooms to eliminate the inuence of external RF signals333
perturbing the signal recieved from the patient during imaging. RF shielding (or Faraday cages) typically takes the334
form of a complete closed layer of around 1 mm of copper sheeting on the MRI room walls, oor, and roof. A typical335
exception to this is a Faraday lter (or waveguide port) through this layer to allow for cabling (power supplies, cooling,336
or similar) to pass into the MRI room without letting in external RF. These waveguides are essentially copper tubing337
with a length that is around 5 times the diameter of the tube. Such an arrangement attenuates any RF signals that338
try to pass through, however acts as a physical hole to allow for the cabling to pass through.339
For MRPT it is wise to assume that the components of the proton pencil beam scanning system and gantry will be340
a potential source of RF that must be shielded from the MRI. The majority of this can be RF shielded by enclosing341
the beamline with a copper shielding layer. The pencil beam would however need to pass through a thin layer of342
copper (or at least an RF conducting material) which will aect the pencil beam properties. The obvious solution343
here (to eliminate the beam passing through a copper or RF layer) is to deliver the pencil beam through an RF lter344
or long copper tube with length at least 5 times the diameter as described earlier. This is well suited to be positioned345
in the gap between the MRI cryostat halves or down the MRI bore.346
4.C. Axial patient couch rotation vs gantry rotation347
In the Sydney MRXT prototype the patient would rotate along their head-feet axis during treatment via an axially348
rotating couch. This eliminates the need to rotate the x-ray source around the patient, and in so, greatly simplies349
the beam delivery process. This does however come at the cost of increased plan complexity from the corresponding350
deformation due to patient rotation. In conventional CT based radiotherapy planning this process would be far351
from ideal. Separate patient CT scans at each beam angle where radiation would be planned and delivered may be352
required, resulting in increased imaging dose and multiple plans that would need co-registration. However in the case353
of MRXT/MRPT the planning images are zero-dose, and the planning/treatment process is expected to be real-time354
and adaptive beyond the rst fraction. Therefore no issues with excess imaging dose will be present, and planning355
datasets would be available for all patient anatomies treated. Another issue is potential patient discomfort with the356
rotation during treatment. A limited angle of couch rotation may reduce this discomfort. The advantage of MRPT357
with a rotating patient would be a major reduction in the cost of the unit. Without the need for a gantry one only358
needs a static beamline, such as in a \xed-beam" treatment room. An important point to note here is the recent359
work by Yan et al. where the necessity of the proton gantry was studied, based on 10 years of clinical proton therapy360
treatments at MGH in Boston[57]. In this work the most important nding was that >99% of patients treated with361
PBS could be treated with a xed beam arrangement. In Section 5.A.1 and 5.B.1 we detail MRPT prototype designs362
with gantry-less or xed beamlines. Such designs would clearly be less complicated and less expensive. The driving363
force therefore behind gantry enabled designs (Section 5.A.2 and 5.B.2) would be the ability to provide an essentially364
unrestricted beam entry angle around the patient, or more precisely, the best possible healthy tissue sparing with365
maximum patient comfort.366
4.D. Beam monitoring systems367
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Current methods for PBS monitoring typically involve the use of multi-wire ion chamber arrays to determine the368
location of the pencil beam at any time during scanning. In the case of MRPT the ion chamber arrays may be located369
in strong MRI fringe elds. For example the IBA Universal Head has the ion chamber located at approximately 850 mm370
from the isocentre. In the Sydney 1 T split-bore MRI design this equates to a fringe eld of around 0.25 T. The overall371
impact that this will have on their operation is essentially unknown at this point in time. With regards to fundamental372
energy deposition processes, in air a proton pencil beam gives rise to secondary electrons which are ultimately the373
particles collected by the ion chamber wires. These are generated through either multiple Coulomb scattering within374
the thin windows of the ion chamber covers or with air molecules surrounding the wires. In the default case (B =375
0 T) these secondary electrons travel away from the pencil beam in a symmetrical forwardly directed nature and so376
the ion chamber collects an accurate representation of each pencil beam. In the presence of a fringe eld, there may377
be dramatic changes to this process as the secondary electrons are easily moved by the strong magnetic elds. This378
area of MRPT development will require investigation. Modelling may provide some early insight into the expected379
performance of multi-wire arrays however experimental testing will ultimately be required to conrm the accuracy of380
such devices in magnetic elds.381
4.E. Pencil beam scanning correction382
Based on the discussion in Sections 3.B.1., it can be forseen that the vast majority of the pencil beam scanning383
correction process to be software based. In particular, calibrations will be performed which map out the fringe384
deections for a particular MRPT system, and direct corrections applied to the scanning magnet currents for each385
desired spot. However if this is not feasible, for example the scanning magnets are not strong enough to recover the386
natural deections encountered, then a solution would be to globally oset or twist the entire PBS assembly and387
beamline to account for these deections seen. We note that this may only be an issue for an MRPT system that is388
perpendicular in orientation, since this sets up a transverse deection. For an inline system the deection is a rotation389
about the beam central axis.[22].390
5. POTENTIAL MRPT SYSTEMS391
Throughout this section we will demonstrate the concept of MRI-guided proton therapy using a model of the 1 T392
split-bore MRI used in the Sydney MRPT protoype. This is chosen as we have an accurate knowledge of the fringe393
eld for this specic design[44]. Dierent magnet-to-proton beamline designs are also possible, with dierent eld394
strengths repectively. To give credibility to the concept of MRPT the key elements (i.e. the PBS assembly) of the IBA395
Universal head are shown in the position that they would be naturally with respect to a patient. We also introduce396
elements that would be unique to MRPT - an RF shielding layer to decouple the MRI from beamline, and novel397
dosimetry systems for PBS inside fringe magnetic elds. Finally the two beam-to-magnetic eld orientations familiar398
with MRXT are presented (perpendicular and inline) for systems where either the patient axially rotates (gures 3399
and 5), or there is a gantry present (gures 4 and 6), in order for multiple beam angles to be delivered. In each gure400
the basics of a surrounding radiation bunker are shown and the footprint described detailing the full proton beamline401
from accelerator to nozzle. A unique requirement of the systems with rotating gantry is that the mass of the MRI402
scanner must be considered - in the current 1 T system this is around 12,000 kg.403
5.A. Perpendicular orientation system404
5.A.1. Rotating couch design405
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(a) (b)
Figure 3: MRPT prototype in the perpendicular orientation with an axially rotating couch design (no gantry). (a)
shows a 3D cutaway view while (b) shows a topview of the full bunker layout. An RF shield boundary is shown
decoupling the MRI from the proton beamline (dashed line). The remaining proton beamline components are indicated
by generic volumes such as scanning magnets, focusing quadrupoles, vacuum tubes, dipole magnets, energy selection
system and synchrocyclotron. The overall size of the bunker oorplan is 12x18 m2.
Figure 3 displays a perpendicular orientation MRPT system with an axially rotating couch (non-gantry). Part (a)406
displays a 3D image showing a cutaway view of the MRI scanner and proton beamline. In this orientation the PBS407
assembly directs a pencil beam through the magnet split-bore gap. The gross deection of the pencil beam via the408
fringe eld will be either up or down (depending on the MRI source coil current direction). In gure 3 (b) a topview409
is shown which details the full layout of the radiation treatment bunker. The RF boundary is also indicated to isolate410
the MRI from the proton beamline. 2 m of concrete shielding is present on all walls and the MRI is shielded from411
the accelerator room and energy selection system. Additional magnetic shielding of the MRI fringe eld beyond the412
bunker may be required depending on the location. The overall size of the bunker oor plan is 12x18 m2.413
414
5.A.2. Rotating gantry design415
Figure 4 shows the perpendicular MRPT design with gantry (static couch). The design shown has the primary416
feature of a centrally mounted concrete pillar which houses the 12,000 kg MRI. By nature, this column prevents417
complete gantry 360 rotation and so a range of 300 (-150 to +150) is estimated with the missing 60 zone being418
through the patient couch. The beamline would be mounted within a large barrel-style gantry that would be supported419
by rollers at the base. The RF shield would also need to wrap around the MRI scanner. In terms of bunker size the420
rotating gantry only adds a few meters in the width direction to the non-gantry design. The total footprint of the421
proposed layout is 14x18 m2.422
5.B. Inline Orientation System423
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(a) (b)
Figure 4: Diagram of the MRI guided proton therapy bunker layout in the perpendicular orientation. (a) 3D cutaway
view (b) Topview detailing the entire bunker oorplan. The total footprint of the proposed layout is 14x18 m2.
5.B.1. Rotating couch design424
Figure 5 displays the inline orientation system with an axially rotating couch (non-gantry). In this case the PBS425
assembly directs a pencil beam straight down the MRI bore. The gross deection of the pencil beam via the fringe426
eld will be rotation around the beam central axis either clockwise or anti-clockwise (depending on the MRI source427
coil current direction).428
429
5.B.2. Rotating gantry design430
Figure 6 shows an example case of the rotating gantry design with inline magnetic eld. In this case the entire431
MRI system needs rotating, a unique engineering concept that appears feasible; we note the 0.5 T eld MRI system in432
the Aurora RT design has a unique rotating biplanar MRI. For support of a 12,000 kg MRI and proton beam gantry433
a large barrel-style gantry is envisaged as shown. The overall bunker size is identical to the perpendicular rotating434
gantry model at 14x18 m2.435
6. TOWARDS MRPT436
Based on the ground-breaking advances seen through the development of MRXT, it could be expected that the437
development of MRPT will follow soon. In sections 3 and 4 we have covered the various software and hardware438
elements that we predict to be important in the eventual realization of MRPT. In this section we list our predictions439
for some of these key milestones. These developments will likely take a path that is determined by the utilization of440
existing technology coupled with gradual integration of the many components required.441
442
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(a) (b)
Figure 5: MRPT prototype in the Inline orientation with an axially rotating couch design (no gantry). (a) shows a
3D cutaway view while (b) shows a topview of the bunker layout. The overall size of the bunker oorplan is 12x18
m2.
(a) (b)
Figure 6: Diagram of the MRI guided proton therapy bunker layout in the Inline orientation. (a) 3D cutaway view.
(b) Topview detailing the bunker layout. In the design shown the gantry would be able to rotate from approx. -150
to + 150 deg. The total footprint of the proposed layout is 14x18 m2.
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6.A. Scanning magnet operation in MRI fringe elds443
This exercise may be performed over several stages, and need not involve a complete proton therapy beamline. For444
example a standalone pencil beam scanning unit may be tested in the vicinity of an MRI scanner. This would involve445
operating the scanning magnets at coil currents covering the full range of clinical treatment scenarios whilst recording446
MR images on a distortion phantom. The fringe eld of the scanning magnet assembly may interfer with the MRI447
and visa-versa. Image quality can be assessed directly by examining the distortion phantom image quality, while the448
scanning ability can be deduced from magnetic eld measurements taken inside the scan magnet deection volumes.449
If successful, then no signicant changes would be expected once incorporated into a full static proton beamline with450
particles.451
452
6.B. MRI-only proton therapy planning453
Successful MRI-only planning will be self evident starting from phantom studies. For example, anatomically454
accurate phantoms with various tissue analog inserts can be imaged in both CT and MRI systems with identical455
setups. From there identical plans can be made and experimental testing performed with dosimeters such as lm456
present to verify the dosimetry dierences between the two approaches. The dose calculation component of this457
dose planning process can also be performed in the Monte Carlo environment to compare predictions. Using these458
approaches it can be expected that incremental improvements will be acheived at regular intervals in progressing the459
accuracy of MRI-only data for dose plannng.460
461
6.C. Pencil beam scanning monitoring462
Static beamline systems tted with a pencil beam scanning system may be sucient to examine this area of research463
in the early stages. It could be possible to emulate the fringe eld of an MRI with a portable Helmholtz coil or similar464
system. Pencil beam monitors could be placed inside and measurements performed of the changes introduced by the465
magnetic eld. Experimental work coupled with Monte Carlo modelling would be expected to accelerate any further466
development required to make such systems operate sucessfully in magnetic elds.467
468
6.D. MRI compatible gantry development469
Beyond the early stage static beamline prototype systems, research into complete integrated gantry designs may470
naturally follow. Introduction of existing gantry components, such as dipole bending magnets and gantry structures,471
into the fringe eld of a non-clinical MRI system may be a realistic rst approach. In parallel with this, modelling472
should be an attractive alternate method to predict the performance of a full integrated system. Condence would be473
gained from the prelimary experiments before construction of larger protoype designs.474
475
6.E. Clinical trials476
Similar to MRXT, clinical trials would form an important element in the implementation of MRPT. Current CT-477
planning based proton therapy is indicated as being superior to CT-planning for photons for around 20% of cancer478
sites[58]. A fundamental argument in the desire to create MRPT is that the modality will be improved. This naturally479
would convert to greater superiority of proton beams over photons for even more cancer sites. Clinical trials will be480
the purest measure of the success of MRPT. As shown in gure 1, we envisage that common intrafractional static481
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cancer sites such as brain to be investigated initially. Slighty more mobile sites such as prostate and head and neck482
would be next to be investigated. Finally, the more challenging dynamic intrafractional motion tumor sites would be483
examined such as lung, liver and abdomen.484
7. DISCUSSION AND CONCLUSIONS485
Protons were rst regarded as a potential particle for use in radiotherapy by Robert Wilson in 1946[59]. The rst486
reported treatments followed in 1955 at Lawrence Berkeley Laboratory[60], and then after much delay, a hospital based487
treatment program commenced at the Loma Linda University Medical Centre in 1990. Between 1990 and 2008 proton488
therapy continually spread and became recognized as a superior particle for radiotherapy treatments such as skull based489
tumors and paediatric cases where a low integral dose is important due to the nite range of protons. In 2009, Smith490
published a Vision 20/20 article entitled \Proton Therapy"[61]. In this paper, the overwhelming predictions for the491
coming decade were that intensity modulated proton beam therapy would be a key element in bringing proton therapy492
forward. Along with this, several new centres were anticipated, and the cost of proton therapy was expected to decrease493
dramatically with advances in accelerator technology and single room ganty solutions becoming avaliable. Based on494
analysis of data from the PTCOG website[62], in 2009 about 52 proton beamlines were in operation worldwide. As495
of December 2016, about 162 are now in operation. It would appear that these predictions of the rapid expansion496
of proton therapy to be in good agreement with, if not exceed, the predictions of Smith from 2009. However rather497
interestingly, there was very little discussion on image guidance in the article. In fact, proton-CT was discussed as a498
potential technology that could improve treatment vercation or planning accuracy. There was a very brief mention499
of anticipated cone-beam CT development, but no mention of MRI. In the 7 years from 2009-2016 we have witnessed500
a rapid progression of image guided radiotherapy for x-ray beam therapy. The bar has been raised for expectations on501
how we guide a patients' radiation beam, and how we use images for dose planning. As described in detail throughout502
the current article, the latest milestone in x-ray beam radiotherapy is that of real-time MRI guidance. It has arguably503
been these developments that have pressured a dramatic shift in the proton therapy community. Cone-beam CT[63]504
and even in room CT systems are now in operation in several proton therapy centres[64]. We therefore predict505
that real-time MRI guided proton beam therapy, MRPT, is potentially the next major advance in current proton506
beam radiotherapy practice. It will in principle oer enhancements that are unique to proton beam therapy, and507
should benet the modality more than what MRI guidance oers x-ray therapy. The steps required to realize this508
new technology will be both software and hardware based. Software processes will need to be developed for robust509
planning and guidance with real-time MR images specic to proton beam therapy. Signicant engineering work on510
new gantry designs will need to be performed. Further to this, it is expected that work will be required to ensure that511
beam delivery verication methods are accurate and support the concept of a more targeted radiotherapy. MRPT512
promises to expand on and further improve the current best quality treatment oered for various cancer sites by pure513
proton therapy. This will strengthen the visions from 1946 by Robert Wilson regarding the use of proton beams for514
cancer therapy, albeit some 80 years down the track.515
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